Using Checkpoint Blockade Inhibitors in Relapsed Hematologic Malignancies After Stem Cell Transplant

December 10, 2017
Matthew S. Davids, MD

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.<br /> <br /> &nbsp;

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.